14 completed, 2 terminated, 1 recruiting, 1 unknown. 10 Phase 2, 4 Phase 3, 3 Phase 4, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Recruiting 1, Terminated 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow ulipristal: new trials by email Literature Review of ulipristal trials Research Report on ulipristal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mammogram Pretreatment With Ulipristal Acetate Biospecimen Collection, Magnetic Resonance Imaging, Mammogram - Mammography Screening, Breast Density | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 26 | 2026-08-21 | 2026-09-03 |
| UA Versus UAE in Treatment of Fibroids Ulipristal Oral Tablet, Uterine artery embolization - Uterine Fibroid | Phase 4 | Completed | Ain Shams Maternity Hospital | 70 | 2019-03-13 | 2021-04-06 |
| Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned Vilaprisan, BAY1002670, Ulipristal - Leiomyoma | Phase 1 | Terminated | Bayer | 10 | 2017-11-16 | 2021-01-06 |
| Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids Vilaprisan (BAY1002670), Vilaprisan (BAY1002670, Ulipristal - Leiomyoma | Phase 2 | Completed | Bayer | 120 | 2015-06-01 | 2016-11-22 |
| Ulipristal for Endometriosis-related Pelvic Pain Ulipristal - Endometriosis | Phase 4 | Completed | Northwestern University | 1 | 2015-02-01 | 2024-05-16 |
| Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy GnRHa, Ulipristal - Fibroids | Phase 4 | Unknown | Amsterdam UMC, location VUmc | 100 | 2014-12-01 | 2016-11-03 |
| CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women CDB-2914 - Urogenital Abnormalities | Early Phase 1 | Withdrawn | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2011-11-08 | 2019-12-17 | |
| PGL4001 Versus Placebo in Uterine Myomas PGL4001 (ulipristal) and iron, PGL4001 matching placebo and iron - Uterine Myomas | Phase 3 | Completed | PregLem SA | 241 | 2008-10-01 | 2012-12-13 |
| Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914 CDB-2914 - Contraception | Phase 2 | Completed | Population Council | 55 | 2008-10-01 | 2017-08-15 |
| Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge CDB-2914 (ulipristal acetate), Placebo - Contraception | Phase 2 | Completed | HRA Pharma | 35 | 2008-05-01 | 2010-08-25 |
| Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception CDB-2914, Levonorgestrel - Contraception | Phase 3 | Completed | HRA Pharma | 2221 | 2007-04-01 | 2022-05-03 |
| Safety and Efficacy of CDB-2914 for Emergency Contraception CDB-2914 - Emergency Contraception | Phase 3 | Completed | HRA Pharma | 1623 | 2006-11-01 | 2021-09-21 |
| Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo - Leiomyoma | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 72 | 2006-02-01 | 2024-07-15 |
| Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914 - Premenstrual Syndrome, PMS | Phase 2 | Terminated | National Institute of Mental Health (NIMH) | 5 | 2004-07-01 | 2017-08-25 |
| Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914 VA2914 - Contraception, Gynecologic Diseases | Phase 2 | Completed | HRA Pharma | 48 | 2004-01-01 | 2010-06-17 |
| Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist CDB-2914 - Leiomyoma | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 56 | 2002-09-02 | 2019-12-17 |
| Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914 CDB-2914, COB-2914 - Healthy | Phase 1 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 15 | 2002-05-01 | 2008-03-04 |
| Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause CDB 2914 - Postmenopause | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 58 | 2001-01-01 | 2008-03-04 |
| Efficacy Trial of CDB 2914 for Emergency Contraception CDB-2914, levonorgestrel - Emergency Contraception | Phase 2 / Phase 3 | Completed | University of Pittsburgh | 1672 | 1999-09-01 | 2007-12-17 |
Leiomyoma (6) · Metrorrhagia (2) · Constipation (1) · Depression (1) · Dysmenorrhea (1) · Endometriosis (1) · Genital Diseases, Female (1) · Hemorrhage (1) · Menorrhagia (1) · Myofibroma (1) · Premenstrual Dysphoric Disorder (1) · Premenstrual Syndrome (1) · Urogenital Abnormalities (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (4) · HRA Pharma (4) · Bayer (2) · Ain Shams Maternity Hospital (1) · Amsterdam UMC, location VUmc (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute of Mental Health (NIMH) (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Population Council (1) · PregLem SA (1) · University of Pittsburgh (1)
United States (11) · United Kingdom (3) · Belgium (2) · Chile (2) · Czechia (2) · Dominican Republic (2) · Hungary (2) · Netherlands (2) · Austria (1) · Bulgaria (1) · Egypt (1) · Finland (1) · France (1) · Germany (1) · India (1)
Abigail Liberty (1) · Alicia Y Christy, M.D. (1) · Anna F Glasier, MD (1) · Diana Blithe, PhD (1) · Dr Elke Bestel (1) · Lynnette K Nieman, M.D. (1) · Lynnette K Nieman, MD (1) · Paul Fine, MD (1) · Pedro E Martinez, M.D. (1) · Philippe Bouchard, MD (1) · Serdar Bulun (1) · Wouter Hehenkamp, PhD (1)
PMID 17077229, PMID 17579200, PMID 18448745, PMID 20093897, PMID 20116841, PMID 20634186, PMID 20881264, PMID 22296075, PMID 24457604, PMID 30239831, PMID 30871768, PMID 32033718, PMID 32559602
1ZIAHD000637-17 (1), 2014 (1), 2017 (1)